Association of XIST/miRNA155/Gab2/TAK1 cascade with the pathogenesis of anti-phospholipid syndrome and its effect on cell adhesion molecules and inflammatory mediators.
Female
Humans
Pregnancy
Abortion, Spontaneous
Antiphospholipid Syndrome
Cell Adhesion Molecules
/ genetics
Inflammation Mediators
Intercellular Adhesion Molecule-1
/ metabolism
MicroRNAs
/ genetics
RNA, Long Noncoding
/ genetics
Thrombosis
/ etiology
Tumor Necrosis Factor-alpha
/ genetics
Vascular Cell Adhesion Molecule-1
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
09
03
2023
accepted:
17
10
2023
medline:
3
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
Anti-phospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis and miscarriage events. Still, the molecular mechanisms underlying APS, which predisposes to a wide spectrum of complications, are being explored. Seventy patients with primary and secondary APS were recruited, in addition to 35 healthy subjects. Among APS groups, the gene expression levels of XIST, Gab2, and TAK1 were higher along with declined miRNA155 level compared with controls. Moreover, the sera levels of ICAM-1, VCAM-1, IL-1ꞵ, and TNF-α were highly elevated among APS groups either primary or secondary compared with controls. The lncRNA XIST was directly correlated with Gab2, TAK1, VCAM-1, ICAM-1, IL-1ꞵ, and TNF-α. The miRNA155 was inversely correlated with XIST, Gab2, and TAK1. Moreover, ROC curve analyses subscribed the predictive power of the lncRNA XIST and miRNA155, to differentiate between primary and secondary APS from control subjects. The lncRNA XIST and miRNA155 are the upstream regulators of the Gab2/TAK1 axis among APS patients via influencing the levels of VCAM-1, ICAM-1, IL1ꞵ, and TNF-α which propagates further inflammatory and immunological streams. Interestingly, the study addressed that XIST and miRNA155 may be responsible for the thrombotic and miscarriage events associated with APS and provides new noninvasive molecular biomarkers for diagnosing the disease and tracking its progression.
Identifiants
pubmed: 37914735
doi: 10.1038/s41598-023-45214-z
pii: 10.1038/s41598-023-45214-z
pmc: PMC10620142
doi:
Substances chimiques
Cell Adhesion Molecules
0
GAB2 protein, human
0
Inflammation Mediators
0
Intercellular Adhesion Molecule-1
126547-89-5
MicroRNAs
0
MIRN155 microRNA, human
0
RNA, Long Noncoding
0
Tumor Necrosis Factor-alpha
0
Vascular Cell Adhesion Molecule-1
0
MAP kinase kinase kinase 7
EC 2.7.11.25
XIST non-coding RNA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18790Informations de copyright
© 2023. The Author(s).
Références
IUBMB Life. 2012 Oct;64(10):825-34
pubmed: 22941947
Pathol Res Pract. 2023 Jun;246:154511
pubmed: 37178618
Brain Behav Immun. 2022 Aug;104:137-138
pubmed: 35688337
Mol Cell Biochem. 2021 Aug;476(8):3009-3020
pubmed: 33791919
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Cell Mol Life Sci. 2021 Jan;78(1):299-316
pubmed: 32193609
Open Med (Wars). 2021 Jan 08;16(1):117-127
pubmed: 33542956
Int J Mol Sci. 2014 Nov 25;15(12):21631-43
pubmed: 25429426
Exp Ther Med. 2021 May;21(5):477
pubmed: 33767772
Arterioscler Thromb Vasc Biol. 2021 Jun;41(6):1987-2005
pubmed: 33827252
Am J Blood Res. 2011;1(2):130-134
pubmed: 22163099
World J Hepatol. 2020 Dec 27;12(12):1211-1227
pubmed: 33442449
Pathol Res Pract. 2023 Aug;248:154590
pubmed: 37295259
Inflammation. 2021 Jun;44(3):965-973
pubmed: 33566259
Yonsei Med J. 2018 Sep;59(7):816-826
pubmed: 30091314
Sci Rep. 2016 Aug 09;6:31375
pubmed: 27502756
Autoimmun Rev. 2015 Sep;14(9):798-805
pubmed: 25989481
Curr Rheumatol Rep. 2022 Jan 5;23(12):85
pubmed: 34985614
Genes Dis. 2022 Apr 29;9(6):1478-1492
pubmed: 36157489
Int Immunopharmacol. 2023 Aug;121:110541
pubmed: 37390564
Front Pharmacol. 2021 Apr 22;12:646521
pubmed: 33967782
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Cell Prolif. 2019 Jan;52(1):e12525
pubmed: 30362186
Nat Immunol. 2005 Nov;6(11):1087-95
pubmed: 16186825
Life Sci. 2023 Feb 15;315:121364
pubmed: 36610639
Toxicol Lett. 2021 Sep 1;347:67-77
pubmed: 33865919
Nucleic Acids Res. 2021 Jan 8;49(D1):D545-D551
pubmed: 33125081
Circ Res. 2001 Feb 2;88(2):245-50
pubmed: 11157679
Front Immunol. 2022 Jul 04;13:932181
pubmed: 35860235
Bioorg Chem. 2023 Oct;139:106743
pubmed: 37490810
Adv Rheumatol. 2019 May 15;59(1):20
pubmed: 31092290
Bioinformatics. 2020 Apr 15;36(8):2628-2629
pubmed: 31882993
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20194-9
pubmed: 24282294
Bioinformatics. 2013 Jul 15;29(14):1830-1
pubmed: 23740750
Rheumatology (Oxford). 2021 Jan 5;60(1):288-296
pubmed: 32756998
Cell Biochem Funct. 2019 Jul;37(5):348-358
pubmed: 31066476
Rheumatology (Oxford). 2018 Sep 1;57(9):1669-1674
pubmed: 29873766
Front Cell Dev Biol. 2021 Jun 10;9:645647
pubmed: 34178980
Inflammation. 2019 Feb;42(1):255-263
pubmed: 30209639
Lupus. 2022 Mar;31(3):354-362
pubmed: 35157809
Am J Reprod Immunol. 2010 Nov;64(5):307-15
pubmed: 20528832
Transpl Immunol. 2022 Oct;74:101666
pubmed: 35809813
Clin Cancer Res. 2009 Jul 1;15(13):4288-91
pubmed: 19509136
Cell Death Discov. 2018 Feb 21;4:35
pubmed: 29531832
Trends Pharmacol Sci. 2012 Oct;33(10):522-30
pubmed: 22795313
J Biol Chem. 2022 Apr;298(4):101773
pubmed: 35218771
Pathol Res Pract. 2023 Jul;247:154584
pubmed: 37267724
FEBS Lett. 2002 Mar 27;515(1-3):1-7
pubmed: 11943184
ACS Chem Neurosci. 2023 Mar 15;14(6):1107-1118
pubmed: 36878000
Med Sci Monit. 2019 Aug 27;25:6429-6435
pubmed: 31452526
J Rheumatol. 2010 Dec;37(12):2516-22
pubmed: 20952466
Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2013-2020
pubmed: 33660813